BioCryst (BCRX) has shared an announcement.
At BioCryst Pharmaceuticals’ Annual Meeting on June 12, 2024, stockholders passed several key proposals, including the expansion of the Stock Incentive Plan by 7 million shares. Additionally, three directors were elected, Ernst & Young LLP was ratified as the independent accountants for the year, and an advisory vote affirmed the company’s executive compensation. The decisions were made with a clear majority, showcasing stockholder support for the company’s strategic direction and governance.
For a thorough assessment of BCRX stock, go to TipRanks’ Stock Analysis page.
